Attila Feher1, Nabil E Boutagy2,3, Evangelos K Oikonomou1, Yi-Hwa Liu1, Edward J Miller1, Albert J Sinusas1,4,5, Monique Hinchcliff6,7. 1. Section of Cardiovascular Medicine, Department of Internal Medicine (A.F., E.K.O., Y.-H.L., E.J.M., A.J.S.). 2. Vascular Biology and Therapeutics Program (N.E.B.). 3. Department of Pharmacology (N.E.B.). 4. Department of Radiology and Biomedical Imaging (A.J.S.). 5. Department of Biomedical Engineering, Yale University, New Haven, CT (A.J.S.). 6. Section of Rheumatology, Allergy & Immunology, Department of Internal Medicine (M.H.). 7. Yale School of Medicine, New Haven, CT (M.H.).
Abstract
BACKGROUND: Coronary microvascular dysfunction has been described in patients with autoimmune rheumatic disease (ARD). However, it is unknown whether positron emission tomography (PET)-derived myocardial flow reserve (MFR) can predict adverse events in this population. METHODS: Patients with ARD without coronary artery disease who underwent dynamic rest-stress 82Rubidium PET were retrospectively studied and compared with patients without ARD matched for age, sex, and comorbidities. The association between MFR and a composite end point of mortality or myocardial infarction or heart failure admission was evaluated with time to event and Cox-regression analyses. RESULTS: In 101 patients with ARD (88% female, age: 62±10 years), when compared with matched patients without ARD (n=101), global MFR was significantly reduced (median: 1.68 [interquartile range: 1.34-2.05] versus 1.86 [interquartile range: 1.58-2.28]) and reduced MFR (<1.5) was more frequent (40% versus 22%). MFR did not differ among subtypes of ARDs. In survival analysis, patients with ARD and low MFR (MFR<1.5) had decreased event-free survival for the combined end point, when compared with patients with and without ARD and normal MFR (MFR>1.5) and when compared with patients without ARD and low MFR, after adjustment for the nonlaboratory-based Framingham risk score, rest left ventricular ejection fraction, severe coronary calcification, and the presence of medium/large perfusion defects. In Cox-regression analysis, ARD diagnosis and reduced MFR were both independent predictors of adverse events along with congestive heart failure diagnosis and presence of medium/large stress perfusion defects on PET. Further analysis with inclusion of an interaction term between ARD and impaired MFR revealed no significant interaction effects between ARD and impaired MFR. CONCLUSIONS: In our retrospective cohort analysis, patients with ARD had significantly reduced PET MFR compared with age-, sex-, and comorbidity-matched patients without ARD. Reduced PET MFR and ARD diagnosis were both independent predictors of adverse outcomes.
BACKGROUND: Coronary microvascular dysfunction has been described in patients with autoimmune rheumatic disease (ARD). However, it is unknown whether positron emission tomography (PET)-derived myocardial flow reserve (MFR) can predict adverse events in this population. METHODS: Patients with ARD without coronary artery disease who underwent dynamic rest-stress 82Rubidium PET were retrospectively studied and compared with patients without ARD matched for age, sex, and comorbidities. The association between MFR and a composite end point of mortality or myocardial infarction or heart failure admission was evaluated with time to event and Cox-regression analyses. RESULTS: In 101 patients with ARD (88% female, age: 62±10 years), when compared with matched patients without ARD (n=101), global MFR was significantly reduced (median: 1.68 [interquartile range: 1.34-2.05] versus 1.86 [interquartile range: 1.58-2.28]) and reduced MFR (<1.5) was more frequent (40% versus 22%). MFR did not differ among subtypes of ARDs. In survival analysis, patients with ARD and low MFR (MFR<1.5) had decreased event-free survival for the combined end point, when compared with patients with and without ARD and normal MFR (MFR>1.5) and when compared with patients without ARD and low MFR, after adjustment for the nonlaboratory-based Framingham risk score, rest left ventricular ejection fraction, severe coronary calcification, and the presence of medium/large perfusion defects. In Cox-regression analysis, ARD diagnosis and reduced MFR were both independent predictors of adverse events along with congestive heart failure diagnosis and presence of medium/large stress perfusion defects on PET. Further analysis with inclusion of an interaction term between ARD and impaired MFR revealed no significant interaction effects between ARD and impaired MFR. CONCLUSIONS: In our retrospective cohort analysis, patients with ARD had significantly reduced PET MFR compared with age-, sex-, and comorbidity-matched patients without ARD. Reduced PET MFR and ARD diagnosis were both independent predictors of adverse outcomes.
Authors: Inderjit Singh; Rudolf K F Oliveira; Robert Naeije; William M Oldham; Mariana Faria-Urbina; Aaron B Waxman; David M Systrom Journal: Rheumatology (Oxford) Date: 2021-03-02 Impact factor: 7.580
Authors: Mariko L Ishimori; Rebecca Martin; Daniel S Berman; Pavel Goykhman; Leslee J Shaw; Chrisandra Shufelt; Piotr J Slomka; Louise E J Thomson; Jay Schapira; Yuching Yang; Daniel J Wallace; Michael H Weisman; C Noel Bairey Merz Journal: JACC Cardiovasc Imaging Date: 2011-01
Authors: A Sulli; M Ghio; G P Bezante; L Deferrari; C Craviotto; V Sebastiani; M Setti; A Barsotti; M Cutolo; F Indiveri Journal: Rheumatology (Oxford) Date: 2004-01-20 Impact factor: 7.580
Authors: Katherine P Liao; Jie Huang; Zeling He; Gabrielle Cremone; Ethan Lam; Jon M Hainer; Victoria Morgan; Courtney Bibbo; Marcelo Di Carli Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Ashley S Manchanda; Alan C Kwan; Mariko Ishimori; Louise E J Thomson; Debiao Li; Daniel S Berman; C Noel Bairey Merz; Caroline Jefferies; Janet Wei Journal: Front Cardiovasc Med Date: 2022-04-15